Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.04 - $45.00
Previous CloseN/A
Volume109.32K
Average Volume (3M)439.79K
Market Cap
$330.05M
Enterprise Value$194.71M
Total Cash (Recent Filing)$22.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.26
Next Earnings
May 12, 2025EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding27,119,823
10 Day Avg. Volume445,235
30 Day Avg. Volume439,792
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.29
Price to Cash Flow (P/CF)-307.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.28
Enterprise Value/Ebitda-2.79
Forecast
1Y Price Target
$66.00Price Target Upside412.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe company expects to present interim data from its Phase II LunairCF study, showing progress in clinical development of ARCT-032 for cystic fibrosis treatment.
Regulatory ApprovalsThe company's proprietary STARR and LUNAR technologies have received recent regulatory approvals, which could bolster its credibility and potential market reach.
Bears Say
Financial PerformanceCollaborative revenue for Arcturus in 2025 is reduced from $138.4 million to $65 million reflecting the winding down of Kostaive clinical development efforts.
Investor SentimentQuestions on vaccine sentiment and commercial prospects have waned investor interest more broadly.
---
Ownership Overview
8.43% Insiders
30.91% Mutual Funds
0.47% Other Institutional Investors
38.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $8.04 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $330.05M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 17 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Mar 06, 2025. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.548 by -$0.562.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.18.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,119,823 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.548. Following the earnings report the stock price went down -8.892%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
---
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.00 (412.02% Upside)
$66.00 (412.02% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 296.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.70%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
-19.87%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics (ARCT) is a biotechnology company specializing in the development of RNA-based medicines using its proprietary technologies. The company focuses on leveraging its innovative platforms to create therapies for rare diseases and infectious diseases. Arcturus' core products include mRNA therapeutics and vaccines, designed to address unmet medical needs in a variety of therapeutic areas.
---
ARCT Company Deck
---
ARCT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Arcturus Therapeutics. While there were significant achievements such as the European approval of KOSTAIVE and progress in various clinical programs, these were offset by financial challenges including decreased revenue and increased net loss. The company's strong cash position and expected cash runway provide some reassurance.Read More>---
ARCT Stock 12 Month Forecast
Average Price Target
$66.00
▲(412.02% Upside)
Technical Analysis
Oruka Therapeutics
―
Verastem
―
ATAI Life Sciences
―
2seventy bio
―
Aura Biosciences Inc
―
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-32.73%
reiterated a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -32.73% per trade.
---